Company: STAA
Filing Date: 2025-09-29
Form Type: DFAN14A
Source: 0001213900-25-093211
Chunk: 4

Company: STAAR SURGICAL CO
Filing Date: 2025-09-29
Form: DFAN14A
Chunk 4
---
26/2025                        |

| Neal C. Bradsher |

| Signature: /s/ Neal C. Bradsher 
 Name/Title: Neal C. Bradsher    
 Date: 09/26/2025                |

| Richard T. LeBuhn |

| Signature: /s/ Richard T. LeBuhn 
 Name/Title: Richard T. LeBuhn    
 Date: 09/26/2025                 |

| Natalie R. Capasso |

| Signature: /s/ Natalie R. Capasso 
 Name/Title: Natalie R. Capasso    
 Date: 09/26/2025                  |

| Raymond A. Myers |

| Signature: /s/ Raymond A. Myers 
 Name/Title: Raymond A. Myers    
 Date: 09/26/2025                |

| Jason J. Martin |

| Signature: /s/ Jason J. Martin 
 Name/Title: Jason J. Martin    
 Date: 09/26/2025               |

Exhibit 99.1

Broadwood Capital, Inc.

September 24, 2025

Dear Fellow STAAR Surgical Stockholders,

Broadwood Partners, L.P. and
its affiliates (collectively, “Broadwood,” “we,” “us,” or “our”) have been committed investors
in, and strong supporters of, STAAR Surgical Company (“STAAR” or the “Company”) for more than thirty years. We
provided needed capital to the Company on various occasions and purchased a substantial number of additional shares over time in the public
markets, including as recently as a few months ago. Today, we beneficially own approximately 27.5% of STAAR’s outstanding shares,
making us the Company’s largest stockholder by a significant margin.

We initially invested in STAAR,
and have added to our position over time, because we believe STAAR’s EVO Implantable Collamer® Lens technology is ideally positioned
to emerge as the superior choice for surgeons and patients in the global refractive surgery market. Leading ophthalmologists increasingly
share this opinion, as has been illustrated by published studies around the world and presentations at recent major ophthalmology conferences.
We believe STAAR can capture this multi-billion-dollar market opportunity and drive sustainable, profitable growth and long-term value.

Admittedly, STAAR’s path
as a public company has not always been smooth. Since 2022, macroeconomic headwinds affected the growth of the refractive surgery market.
Additionally, under prior leadership,